An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Status:
Completed
Trial end date:
2021-06-11
Target enrollment:
Participant gender:
Summary
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The
open-label extension phase only will be described in this record. All participants will
receive the same dose of GWP42003-P. However, investigators may subsequently decrease or
increase the participant's dose until the optimal dose is found.